Eric Jonasch

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• TKI resistance is associated with immune dysfunction in ccRCCPreprint

  Research Square · 2026-06-14

• Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers

  UNC Libraries · 2025-12-19

• Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers

  CA A Cancer Journal for Clinicians · 2025-12-13

• Supplementary Data 1 from SETD2 Loss and ATR Inhibition Synergize to Promote cGAS Signaling and Immunotherapy Response in Renal Cell Carcinoma

  2025-11-25

• 1057 Early targeted biologics are associated with improved clinical outcomes in immune-related myocarditis, myositis, and myasthenia gravis

  Regular and Young Investigator Award Abstracts · 2025-11-01

• A multicenter randomized phase II trial of lenvatinib plus everolimus versus cabozantinib in patients with metastatic clear-cell RCC that progressed on PD-1 immune checkpoint inhibition (LenCabo)

  Annals of Oncology · 2025-10-18 · 9 citations

• 66Patient perceptions of biomarker testing in kidney cancer (KC) from the international kidney cancer coalition (IKCC) global patient survey (GPS)

  The Oncologist · 2025-10-01

• PS2-2 Safety profile of belzutifan monotherapy in patients with renal cell carcinoma: a pooled analysis of four clinical trials

  Annals of Oncology · 2025-10-01

• SY23-4 HIF-2 alpha inhibitors - game changers?

  Annals of Oncology · 2025-10-01

• 7Phase 2 trial of metastasis directed radiotherapy without systemic therapy (MRWS) for oligometastatic clear cell renal cell carcinoma (ccRCC) and investigation of circulating tumor DNA (ctDNA)

  The Oncologist · 2025-10-01

• 2631P Unmet needs & disparities in kidney cancer (KC): International kidney cancer coalition (IKCC) global patient survey (GPS)

  Annals of Oncology · 2025-09-01

• 2596MO Phase Ib/II trial of ipilimumab, nivolumab, and ciforadenant (adenosine A2a receptor antagonist) in first-line advanced renal cell carcinoma (RCC), a kidney cancer research consortium study

  Annals of Oncology · 2025-09-01 · 2 citations

• Developing biomarkers and methods of risk stratification: Consensus statements from the International Kidney Cancer Symposium North America 2024 Think Tank

  Urologic Oncology Seminars and Original Investigations · 2025-08-18 · 2 citations

• Real-world challenges and considerations in treating von Hippel-Lindau disease with HIF-2α inhibitors – Authors' reply

  The Lancet Oncology · 2025-07-01

• Phase 1b/2 study of batiraxcept alone and in combination with cabozantinib with or without nivolumab for advanced clear cell renal cell carcinoma

  The Oncologist · 2025-06-01

• Hypoxia-inducible factor-2α (HIF-2α) inhibitor belzutifan in von Hippel-Lindau (VHL) disease–associated neoplasms: 5-year follow-up of the phase 2 LITESPARK-004 study.

  Journal of Clinical Oncology · 2025-05-28 · 4 citations

• Abstract CT132: Phase 2 trial of metastasis directed radiotherapy without systemic therapy (MRWS) for oligometastatic clear cell renal cell carcinoma (ccRCC) and investigation of circulating tumor DNA (ctDNA) as a personalized biomarker

  Cancer Research · 2025-04-25

• Disease Monitoring and Treatment Patterns of von Hippel-Lindau Disease-Associated Renal Cell Carcinoma in the United States

  Clinical Genitourinary Cancer · 2025-04-06 · 1 citations

• A phase II trial of sitravatinib + nivolumab after progression on immune checkpoint inhibitor in patients with metastatic clear cell RCC

  The Oncologist · 2025-04-01 · 3 citations

• Corrigendum

  Ophthalmology · 2025-02-20